Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
eli lilly
6
×
indiana blog main
indiana top stories
life sciences
6
×
national blog main
raleigh-durham blog main
6
×
raleigh-durham top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
crispr
fremanezumab
lasmiditan
migraine
migraine research foundation
novartis
triptans
calcitonin gene-related peptide
What
new
6
×
approval
drug
bio
fda
migraine
roundup
won
class
companies
decades
drugs
pharmaceutical
acute
addresses
amgen
arguments
bails
big
biogen’s
biopharma
biopharmaceutical
brand
bridgebio
candidates
capital
car
causes
commercialized
competitors
condition
congress
congressional
convo
crispr
develop
developed
earlier
eli
emerges
Language
unset
Current search:
new
×
photo
×
" life sciences "
×
" eli lilly "
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines